Active tumor-targeted delivery of PEG-protein via transferrin-transferrin-receptor system

Transferrin (Tf) holds promise as a drug carrier because of overexpress transferring receptors (TfRs) on the surface of tumor cells. The purpose of this work was to conjugate Tf to PEGylated protein (Tf-PEG-protein) to improve tumor-targeted delivery of PEG-protein. After a model protein, β-lactoglo...

Full description

Saved in:
Bibliographic Details
Published in:Journal of drug targeting 2007-01, Vol.15 (10), p.672-683
Main Authors: Jiang, Yanyan, Tang, Guotao, Hong, Minghuang, Zhu, Saijie, Fang, Chao, Shi, Bin, Pei, Yuanying
Format: Article
Language:English
Subjects:
Animals
Antineoplastic Agents - administration & dosage
biodistribution
Biological and medical sciences
Drug Carriers
Female
General pharmacology
Humans
K562 Cells
KB Cells
Lactoglobulins - administration & dosage
Lactoglobulins - pharmacokinetics
Male
Maleimides - administration & dosage
Medical sciences
Mice
PEGylatioin
Pharmaceutical technology. Pharmaceutical industry
pharmacokinetics
Pharmacology. Drug treatments
Polyethylene Glycols - administration & dosage
Proteins - administration & dosage
Rats
Rats, Sprague-Dawley
Receptors, Transferrin - metabolism
Sarcoma 180 - drug therapy
Tissue Distribution
Transferrin - metabolism
transferring
tumor-targeted delivery
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Transferrin (Tf) holds promise as a drug carrier because of overexpress transferring receptors (TfRs) on the surface of tumor cells. The purpose of this work was to conjugate Tf to PEGylated protein (Tf-PEG-protein) to improve tumor-targeted delivery of PEG-protein. After a model protein, β-lactoglobulin B (LG), was modified by the heterobifunctional polyethyleneglycol (PEG), Tf was covalently linked to the distal end of the PEG chains on the PEG-LG (PL) conjugate. The purified Tf-PEG-LG (TPL) contained 1.4 of Tf ligand on one LG molecule. The specificity and affinity of TPL to TfR on two kinds of tumor cells (K562 and KB cells) were assessed. The results demonstrated that, TPL can bind specifically to the TfR on the tumor cell surface and the affinity of the conjugate to TfR was similar to that of native Tf. The pharmacokinetics and biodistribution studies in rodents found that TPL exhibited a significantly delayed blood clearance, the longest tumor resident time and the greatest tumor accumulation, as compared with LG and PL. Such design of the Tf conjugate would suggest a promising approach for active tumor targeting of therapeutic proteins or peptides to target cells.
ISSN:1061-186X
1029-2330
DOI:10.1080/10611860701603414